May 022021
 
Ergomed welcomes Dr. Llew Keltner to its Board as Non-Executive Director

– UK, London –  Ergomed plc (LON: ERGO), a company focused on providing specialized services to the pharmaceutical industry, today announced the appointment of Dr. Llew Keltner, M.D., Ph.D. to its Board as a Non-Executive Director with immediate effect.

“Llew’s outstanding track record in the life sciences industry, with particular focus in oncology and rare disease in the US and globally, will be an invaluable asset for Ergomed. This experience, together with his strong links to the US pharmaceutical and investment communities, are fully aligned with the Company’s strategy to continue our expansion in the US and build our global specialist leadership position. Llew will be a great addition to Ergomed’s Board and on behalf of the Board, I warmly welcome him to his new role.” said Executive Chairman,

The Company also announced that Non-Executive Director, Ian Johnson, is stepping down from the Ergomed Board to focus on his other Board roles.

Dr Miroslav Reljanović commented: “I would also like to thank Ian for his contribution and support of Ergomed throughout his time on the Board. We wish him all the best for the future.”

About Dr. Llew Keltner

Dr. Keltner brings over 30 years of experience across the life sciences sector, holding various senior positions with a particular focus on oncology and rare diseases. He has extensive experience in public and private financings, M&A, the formation of strategic partnerships, and numerous transactions in the CRO, biotech, and pharma sectors. While Chairman of Raptor Pharmaceuticals Inc., a US rare disease company, he led multiple financing rounds, product launches, and the eventual sale of the Company to Horizon Pharmaceuticals in 2016. He was also a member of the Board of Mannkind Corporation through its successful Nasdaq listing, and Immunovaccine Inc. through several successful fundraises.

Dr. Keltner holds the positions of Associate Professor at Case Western Reserve School of Medicine, and Director and Lecturer in Bioethics at Columbia School of Medicine, as well as authoring numerous research papers. He is currently on the Scientific Advisory Boards of several life sciences companies across the United States.

Dr. Llew Keltner said: “Having seen the success and rapid rate of growth at Ergomed, it is hugely exciting to be joining the team. The growth in both the CRO business and PrimeVigilance has been impressive to watch from the outside and the addition of two US acquisitions has transformed the company’s presence and capabilities in the US market. I am looking forward to working with the Board and contributing my expertise in life sciences and US investor relations as the Company continues on its high growth trajectory and becomes a global leader in its chosen markets.”

He holds an MD and a PhD in Biomedical Informatics, both from Case Western Reserve University in Cleveland.

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance, and medical information. Ergomed’s fast-growing services business includes an industry-leading suite of specialist pharmacovigilance solutions, integrated under the PrimeVigilance brand, a full range of high-quality clinical research and trial management services under the Ergomed brand, and an internationally recognized specialist expertise in orphan drug development, under PSR.

For more information: https://www.ergomedplc.com/

Sorry, the comment form is closed at this time.

%d bloggers like this: